Overview

Cabozantinib (Cabozanix) 60 mg tablets exert their effect through unusually broad kinase inhibition, simultaneously engaging MET, VEGFR2 and RET pathways that drive angiogenesis and tumor survival. For technical buyers, this multi-target mechanism rather than a single receptor explains the drug's activity across renal, thyroid and liver cancers. This guide details the molecular basis of that wide therapeutic reach.

How It Works

Cabozantinib is an oral small-molecule inhibitor of multiple receptor tyrosine kinases, most notably MET, VEGFR2, RET, KIT, FLT3 and AXL. By blocking VEGFR2 it starves the tumor of its blood supply, while MET inhibition counters a known escape route that fuels resistance to anti-angiogenic therapy. RET blockade addresses RET-altered medullary thyroid cancer, and AXL targeting interferes with invasive and mesenchymal phenotypes. The convergence of these pathways under one molecule allows a single agent to disrupt both the vascular niche and the proliferative signaling that sustain several tumor types.

Indications

Cabozantinib is indicated for advanced renal cell carcinoma, progressive medullary thyroid cancer and previously treated hepatocellular carcinoma, among other settings. Its utility spans multiple tumor types because the targeted kinases are recurrent drivers across them. Procurement teams should map demand to these distinct indications, since each carries its own treatment-line positioning and volume profile.

Dosage & Administration

The product is supplied as 60 mg film-coated tablets, 30 tablets per box. Dosing is oral, once daily, with dose reductions for toxicity and food-related instructions that vary by strength. Tablets must be swallowed whole and not crushed. Buyers should confirm the 60 mg strength matches the prescribed regimen, because cabozantinib is also marketed in other strengths that are not interchangeable.

Storage & Sourcing

Store below 30 °C in the original container, protected from moisture and light. As a multi-indication oncology agent, cabozantinib should be sourced from authorized manufacturers such as Beacon with full GMP documentation. Verifying certificate of analysis and batch traceability reduces the risk of subpotent or falsified product entering cross-border supply.

FAQ

Q: Why block several kinases instead of just one? Tumors exploit parallel pathways, so blocking only VEGF leaves MET and other routes open. Cabozantinib's breadth closes those escape routes simultaneously.

Q: Which cancers does the MET and RET activity cover? MET blockade addresses anti-angiogenic resistance, while RET inhibition targets medullary thyroid cancer driven by RET alterations.

Q: What documents confirm authentic supply? Request GMP certificates, certificates of analysis and batch numbers, and confirm the manufacturer authorization before distribution.